Portfolio Rapha Capital Management

Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round

By Kevin SlawinApril 22, 2019February 4th, 2021No Comments

Poseida Therapeutics
Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round
April 22, 2019

Previous PostRapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
Next Post3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions